Effects of tropomyosin 4 applied in spinal cord injuries via lentiviral vector recombination and the underlying mechanism:study protocol for a randomized controlled trial
10.3969/j.issn.2095-4344.2016.37.015
- VernacularTitle:原肌球蛋白4通过慢病毒重组体技术应用于脊髓损伤后的作用及机制研究：随机对照实验方案
- Author:
Suyi LUO
;
Wei HUANG
;
Jing WANG
;
Xiyun WANG
;
Jintao LI
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2016;20(37):5573-5579
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Tropomyosin 4 level has been found to be an increase in the spinal cord based on the 2-DE/MALDI-TOF/MS method. However, there is little report about the relationship between tropomyosin 4 and pathogenesis and progress of spinal cord injuries.
METHODS/DESIGN:Randomized control ed trial:rat models of complete spinal cord transection were made and expression levels of tropomyosin 4 at 3-28 days after modeling were determined by two-dimensional electrophoresis, animo acid serie analysis, quantitative PCR and western blot. Experiment for exporing the genetic mechanism:effects of tropomyosin 4 scilencing by lentivirus recomnination technology on the dendrite length of spinal cord neurons in vitro were observed, and its effects on the neurological function of rats after complete spinal cord transaction were assessed through Basso, Beattie, and Bresnahan scoring.
DISCUSSION:This study wil be powered to provide a novel and effective treatment strategy for neurological function recovery after spinal cord transection based on the lentivirus recomnination carrying tropomyosin 4, as wel as optimistic future for clinical gene treatment of complete spinal cord transaction through figuring out the underlying mechanism.
ETHICAL APPROVAL:This study was approved by the Ethics Committee of Kunming Medical University, China. The surgical operation and postoperative care of rats were in line with the rules of Chinese Experimental Animal Protection and Ethics Committee, and the guideline of the National Institutes of Health
